News

TEL：+86-21-33585366（DDT）
     34666753、33588661
FAX：+86-21-34979012
Q Q：  2762556331（Domestic）
      3501899018（Export）
E-mail：info@shyrchem.com
Domestic：sales@shyrchem.com
Export：sales02@shyrchem.com

Your current location：Home > News

Rare disease field welcomes an innovative drug 2024-12-17
Pharmaceutical leader officially launches H-share listing process 2024-12-10
Innovative drugs for hepatitis B treatment are included in the list of proposed breakthrough treatme 2024-12-06
This pharmaceutical company has added "new blood" to the field of anti infection! 2024-12-03
11 kinds of traditional Chinese patent medicines and simple preparations were included in the nation 2024-11-29
Securities firm: Medical equipment sector is expected to enter a high growth performance range 2024-11-26
The National Medical Products Administration has approved 255 medical devices! 2024-11-22
Over $700 million collaboration to develop SSTR2 targeted nuclear drug 2024-11-20
Parkinson's disease new drug application accepted for market launch 2024-11-15
Targeting the Korean biopharmaceutical market 2024-11-11

Pages：1/8 page10 total77 home last next end go to:

Copyright © 2017-2020 SHANGHAI YINGRUI BIOPHARMA CO.,LTD 沪ICP备11038445号-1
TEL：+86-21-33585366(DDT)、34666753 FAX：+86-21-34979012
E-mail：info@shyrchem.com ADD：1885 Metropolitan Road, Minhang District, Shanghai Code：201108